Oct-3/4 is the earliest expressed transcription factor that is known to be crucial in murine pre-implantation development. In this report we asked whether methylation participates in controlling changes in Oct-3/4 expression and thus may play an important role in controlling normal embryogenesis. We show that the Oct-3/4 gene is unmethylated from the blastula stage but undergoes de novo methylation at 6.5 days post-coitum and remains modified in all adult somatic tissues analyzed. Oct-3/4 remains unmethylated in 6.25 days post-coitum epiblast cells when other genes, such as apoAI, undergo de novo methylation. We show that methylation of the Oct-3/4 promoter sequence strongly compromises its ability to direct efficient transcription. Moreover, DNA methylation inhibits basal transcription of the endogenous Oct-3/4 gene in vivo. We found that the Oct-3/4 gene harbors a cis-specific demodification element that includes the proximal enhancer sequence. This element leads to demethylation in embryonal carcinoma cells when the sequence is initially methylated and protects the local region from de novo methylation in post-implantation embryos. These results indicate that in the embryo protection from de novo methylation is not a unique feature of imprinted or housekeeping genes that carry a CpG island, but is also applicable to tissue-specific genes expressed during early stages of embryogenesis. Methylation of Oct-3/4 may be analogous to methylation of CpG islands on the inactive X chromosome that also occurs at later stages of development.
Oct-3/4 is the earliest expressed transcription factor that is known to be crucial in murine pre-implantation development. In this report we asked whether methylation participates in controlling changes in Oct-3/4 expression and thus may play an important role in controlling normal embryogenesis. We show that the Oct-3/4 gene is unmethylated from the blastula stage but undergoes de novo methylation at 6.5 days post-coitum and remains modified in all adult somatic tissues analyzed. Oct-3/4 remains unmethylated in 6.25 days post-coitum epiblast cells when other genes, such as apoAI, undergo de novo methylation. We show that methylation of the Oct-3/4 promoter sequence strongly compromises its ability to direct efficient transcription. Moreover, DNA methylation inhibits basal transcription of the endogenous Oct-3/4 gene in vivo. We found that the Oct-3/4 gene harbors a cis-specific demodification element that includes the proximal enhancer sequence. This element leads to demethylation in embryonal carcinoma cells when the sequence is initially methylated and protects the local region from de novo methylation in post-implantation embryos. These results indicate that in the embryo protection from de novo methylation is not a unique feature of imprinted or housekeeping genes that carry a CpG island, but is also applicable to tissue-specific genes expressed during early stages of embryogenesis. Methylation of Oct-3/4 may be analogous to methylation of CpG islands on the inactive X chromosome that also occurs at later stages of development.
Development is a multistep process involving interactions of a large number of trans-acting factors with specific cis-regulatory elements leading to the activation and repression of many genes. Oct-3/4 is the earliest expressed transcription factor that is known to be crucial in murine pre-implantation development (1) . The Oct-3/4 gene is a member of the POU family of transcription factors; it is expressed in embryonal stem (ES) 1 and in embryonal carcinoma (EC) cells (1, 2) . Oct-3/4 expression is down-regulated in these cells upon induction to differentiate with retinoic acid (RA) (3) (4) (5) (6) (7) (8) . The Oct-3/4 gene is expressed throughout the pre-implantation embryo (6, 9) . Oct-3/4 protein is present in unfertilized oocytes, and the zygotic expression is activated prior to the 8-cell stage (9 -11) . In the embryo Oct-3/4 is abundantly and uniformly expressed in all cells through the morula stage (11) . Its expression is downregulated in trophectoderm cells and becomes restricted to cells of the inner cell mass in the blastocyst (9) . Oct-3/4 expression is high and persists through day 7.5 in the unsegmented presomitic mesoderm, decreasing anteriorly to posteriorly as the somatic lineages form (7) . From day 8.5, expression cannot be detected in any somatic tissue but is restricted to the premigratory progenitor germ cells (9, 12) .
Recently, using conventional gene targeting technology, it was found that the activity of Oct-3/4 is essential for the identity of the pluripotential founder cell population in the inner cell mass (13) . Furthermore, it was shown that a critical amount of Oct-3/4 is required to sustain stem cell self-renewal, and any up-or down-regulation induces divergent developmental programs (14) . A very modest modulation of Oct-3/4 levels in ES cells results in a dramatic readout. Thus, it is now recognized that the mere presence of Oct-3/4 protein does not define pluripotency because it is the level of expression that is the key to regulation.
One of the molecular mechanisms that regulate gene expression is methylation (15) . DNA methylation plays a crucial role in normal embryogenesis by acting in cis to modulate protein-DNA interactions. Several studies have demonstrated that DNA methylation patterns go through dynamic changes during embryogenesis. A global loss of DNA methylation occurs in the mammalian preimplantation embryo prior to the 16-cell morula stage, and the DNA remains unmethylated throughout blastulation (16, 17) . Following implantation, an extensive wave of de novo methylation occurs, and only genes containing CpG islands, such as housekeeping genes, escape this process (16, 18, 19) . At a later stage of development, tissue-specific genes undergo selective demethylation (20, 21) .
Because Oct-3/4 plays a crucial role in regulating initial differentiation decisions in early development and has a unique expression pattern, we studied the dynamics of the generation of its methylation pattern and the role of methylation in controlling Oct-3/4 expression. We have shown previously (22) that treatment of EC cells with RA reduces Oct-3/4 expression that is associated with increased methylation and changes in chromatin structure in the immediate upstream regulatory region that includes the promoter (P) and proximal enhancer (PE) elements. In this study we show that in vivo the Oct-3/4 gene is unmethylated from the blastula stage and starts to undergo de novo methylation at 6.5 dpc. The Oct-3/4 gene remains modified in all adult somatic organs analyzed. We show that during embryogenesis Oct-3/4 remains unmethylated at a time when genome wide methylation occurs; thus it was interesting to find out whether it carries a cis-demethylation element that pro-tects the gene from global modification mechanisms. By using a series of stable transfection assays into EC cells, we have found that the Oct-3/4 gene does harbor a cis-specific demodification element that includes the Oct-3/4 PE sequence. Furthermore, mutagenesis at the protein-binding sites of this sequence clearly affected its demethylation activity. By using a minitransgene containing the PE sequences only, we have shown that in the embryo the PE protects the DNA from de novo methylation in 6.25 dpc epiblast cells, and when it is mutated the sequence becomes methylated. In vitro methylation of the Oct-3/4 upstream sequence inhibits its ability to induce transcription. Moreover, we have shown that DNA methylation inhibits the endogenous Oct-3/4 basal expression in vivo.
EXPERIMENTAL PROCEDURES
Cells-Murine P19 (23) EC cells and L8 cells were maintained as described previously (8) . p53
Ϫ/Ϫ and p53 Ϫ/Ϫ Dnmt1 Ϫ/Ϫ fibroblasts were grown from 9 dpc embryos obtained by mating p53
Ϫ/Ϫ Dnmt1 Ϫ/ϩ mice. These cells (grown in Dulbecco's modified Eagle's medium containing 15% fetal calf serum) appear to be immortal, still not having undergone senescence even after 100 passages. Nearest neighbor analysis (24) revealed that less than 5% of CpG residues in these cells are methylated, as compared with 73% for normal fibroblasts. These cells were treated with 50 ng/ml TSA for 24 h in order to study Oct-3/4 transcription.
Plasmids and Oligonucleotides-The constructs 342 and pOct-luc have been described previously (see Refs. 25 and 26, respectively). pOctPE-luc was constructed by cloning the PCR amplification product spanning positions Ϫ1215 to ϩ155 of the Oct-3/4 upstream region containing the PE and P sequences into the PstI site of pOct-luc. The pre-existing P was deleted by digestion with HindIII-and the plasmid was religated. The primers used were Nsi 2 and Nsi 3.
The following plasmids were constructed by digesting the different constructs with NsiI and subcloning them into the PstI site in plasmid 342.
pPEwt was constructed by cloning the PCR amplification product spanning positions Ϫ1215 to Ϫ900 of the Oct-3/4 PE region. The primers used were Nsi 2 and Nsi 1.
pPEPwt was constructed by cloning the PCR amplification product spanning the Ϫ1215 to ϩ155 positions of the Oct-3/4 PE and P region. The primers used were Nsi 2 and Nsi 3. pPE1A* construct is identical to the above described pPEwt plasmid except for a 16-bp mutation inserted in the 1A site. Two distinct PCR amplification reactions were done on pBluescript KS(Ϫ) containing the Ϫ1215 to Ϫ541 BamHI-SauIIIA upstream region of the Oct-3/4 gene. The primers used were RARE1A and Primer 2 and RARE1Arev and Primer 1. Products were mixed, amplified with Primers 1 and 2, digested with BamHI/ScaI, and subcloned into BamHI/EcoRV sites in pBluescript KS(Ϫ) to create pmRARE1A. pPE1A* was constructed by cloning the PCR amplification product of pmRARE1A using the primers Nsi 1 and Nsi 2 into the PstI site in 342. pPE1B* was constructed by cloning the PCR amplification product spanning positions Ϫ1215 to Ϫ942 of the Oct-3/4 PE region, harboring a deletion of the 1B site. The primers used were Nsi 2 and Nsi 4. pPE1A*1B* construct is identical to the above described pPE1B* plasmid except for a 16-bp mutation inserted in the 1A site. pPE1A*1B* was constructed by cloning the PCR amplification product of pmRARE1A using the primers Nsi 2 and Nsi 4.
pPEP1A*1B* construct is identical to the above described pPEPwt plasmid except for a 16-bp mutation inserted in the 1A site and a 28-bp deletion of the 1B site. pmRARE1A was subjected to PCR amplification with Primer 2 and Primer RARE1Brev; the product was digested with BamHI/ScaI and ligated to ScaI/BamHI fragment from pPEPwt. The ligation fragment was subjected to PCR amplification using the primers Nsi 2 and Nsi 3 and subcloned into the PstI site in 342 to create pPEP1A*1B*. Primers and PCR amplification conditions are described in Table I .
Methylation in Vitro and Transfection-Plasmid DNAs were methylated in vitro as described previously (27) . P19 and L8 cells were transfected by the calcium phosphate precipitation method (28) . Cells (5 ϫ 10 5 ) were plated 24 h before transfection and cotransfected with 15 g of methylated plasmid together with 1.5 g of a plasmid carrying the neo selection gene. Stably transfected cells were selected by G418 (250 mg per ml, Invitrogen), and clonally propagated.
Preparation of Preimplantation and Post-implantation EmbryosPre-implantation embryos were obtained as described previously (29) . The post-implantation embryos were dissected from the uterus of the foster mothers at dpc 6.25, 6.5, 7.5, 8.5, 12.5, or 14.5.
PCR Methylation Analysis-Genomic DNAs were extracted from the following groups: 1) a pool of 10 -20 preimplantation blastocysts; 2) a pool of epiblast cells dissected from 7 embryos of 6.25 dpc; 3) pools of post-implantation embryos at stages 6.5, 7.5, 8.5, 12.5, and 14.5 dpc.
DNA samples were divided into 3 aliquots that were subjected to digestion with PvuII alone and PvuII together with HpaII or HhaI. The PCRs were carried out with 5 ng of DNA using the following primers: for analyzing HpaII sites 1-4 primers Hp1a and Hp1b, Hp2a and Hp2b, Hp3a and Hp3b, Hp4a and Hp4b were used, respectively. In order to analyze the HhaI site, primers Hp3a and Hp4b were used. To assay the J region that lacks HpaII or HhaI sites, we used 5GL-2 and J1110 primers. Primers and PCR amplification conditions are described in Table II .
HpaII and HhaI sites in the first intron of the apoAI gene were studied using "fragment I" primers as described previously (16) .
Whole Cell Extracts (WCEs)-WCEs and electrophoretic mobility shift assays (EMSAs) were done as described previously (30) . 1Awt and mut1A oligonucleotides (described in Table III) were used for EMSAs.
Luciferase Analysis-The differentially methylated pOct-luc or pOctPE-luc constructs were transiently cotransfected with the pCMVRenilla luciferase construct into P19 EC cells using the calcium phosphate precipitation method (28) . Luciferase activity was determined 48 h post-transfection (Dual-luciferase Reporter Assay system kit, Pro- 
5Ј-CCTTGATTTCAGAATCTTGCC-3Ј 5Ј-GCCAAGCTCGGAATTAACCC-3Ј RARE1Brev 5Ј-AAAAGTACTCCCCTGGGGACAACTTCC-3Ј mega) and was corrected for transfection efficiency by measuring the Renilla luciferase activity.
RT-PCR-Total RNA was collected from the cells with Trizol (Sigma) following the manufacturer's instructions. Reverse transcription was carried out following the manufacturer's protocol (Promega). RT-PCR analysis of Oct-3/4 transcription in p53 Ϫ/Ϫ , p53 Ϫ/Ϫ /Dnmt1 Ϫ/Ϫ , and blastocyst cells were carried out using the primers 251L and Oct4-a. PCR was performed using 200 mM of the four dNTPs, 100 ng of each primer, and 0.1 l of [ 32 P]dCTP. A second half-nested PCR was carried out in the same reaction conditions using the following primers: Oct4 -5Ј and Oct4-a. One-third of the reaction products was subjected to electrophoresis on a 7.2% polyacrylamide gel. Primers and PCR amplification conditions are described in Table IV .
Transgenic Mice-The 1141-and 1099-bp DraI fragments, harboring the wt or double mutated Oct-3/4 PE sequences, were isolated from pPEwt and pPE1A*1B* plasmids, respectively. Fragments were purified from low melting point agarose gels by a gel extraction kit (Qiagen). DNA samples were microinjected into the pronucleus of (C57BL/6 ϫ BALB/c)F1 fertilized mouse eggs and transferred into pseudo-pregnant CB6/F1 foster mother. Transgenic mice were identified by PCR amplification using primers DraI-3Ј and Hp1b (Table II) .
Methylation-dependent PCR Analysis of Transgenic Mice-Epiblast cells were isolated from 6 wt PEwt and 13 double mutated PE1A*1B* 6.25 dpc transgenic embryos as described (31) . DNA from the wt and mutated pools of embryos was extracted, and 10 ng were subjected to digestion with PvuII in the presence or absence of HpaII. Products were analyzed by PCR amplification using primers DraI-3Ј and Hp1b (Table  II) flanking HpaII site 1 in the Oct-3/4 PE. As a control, we assayed the J region that lacks HpaII sites using 5GL-2 and J1110 primers. Primers and PCR amplification conditions are described in Table II .
RESULTS

The Generation of Oct-3/4 Methylation Pattern during Embryogenesis and in the Adult-Four HpaII and one
HhaI sites were analyzed in the Oct-3/4 1370-bp upstream region (Fig.  1A) . To study the methylation status of the Oct-3/4 gene in early mouse embryos, genomic DNA was isolated from mouse embryos at various stages of development. We adopted a PCRbased assay in which genomic DNA was subjected to digestion with or without HpaII or HhaI methyl-sensitive restriction enzymes. Digestion conditions were carefully titrated. After digestion, oligonucleotide primers flanking each site were used. A PCR product is observed only when the site is methylated and refractory to digestion. It was shown previously (16) that when properly calibrated, this assay is linear over a wide range of DNA concentrations and can be used to measure accurately the degree of DNA methylation at specific sites. By using this PCR assay, we show that the HhaI and the four HpaII sites tested are clearly unmethylated in blastocysts and in epiblast cells isolated from 6.25 dpc embryos. These sites become methylated in 6.5 dpc embryos almost to the full extent (Fig. 1B) . Control experiments were included to validate our results. Tail DNA and DNA from P19 cells served as controls for methylated and unmethylated DNA, respectively. Moreover, as an internal control, a primer pair that amplifies a J sequence that does not encompass either HpaII or HhaI sites was included in each reaction. As expected, the fragment was amplified from all DNA samples to a similar level (Fig. 1B) . We have quantified the methylation status of each site by PhosphorImager analysis and found that different sites undergo modification to various levels, and for most of these sites the level of methylation is sustained throughout embryogenesis (Fig. 1D) . Similar results were obtained from quantifications of Southern blots containing DNA isolated from 6.5, 8.5, 12.5, and 14.5 dpc embryos, P19 cells, and murine tails (data not shown).
In order to investigate whether this pattern of modification serves as the prototype for the basic stable methylation pattern in somatic cells, we analyzed the methylation status of the Oct-3/4 upstream regulatory region in adult kidney and tail DNA. As can be seen in Fig. 1D , the cleavage patterns of all sites analyzed of both DNA samples were roughly similar to those found in 8.5-day embryos. Results from PhosphorImager analysis of the corresponding Southern blots were graphed (Fig. 1E) , and it is interesting to note that the HhaI site located in the P region and the juxtaposed HpaII site 3 are almost fully methylated, serving as a core methylation center, whereas sites flanking this center (HpaII sites 1, 2, and 4) are partially methylated. These experiments clearly show that the methylation pattern established during development faithfully propagates itself to adulthood.
The PE Fragment Directs EC-specific Demethylation-The apoA1 gene, similar to other tissue-specific genes analyzed, undergoes de novo methylation due to the onset of global methylation that occurs at post-implantation embryos (16, 17) . As can be seen in Fig. 1C , the apoA1 sequences are methylated in the 6.25 dpc epiblast cells, at the time when Oct-3/4 is still unmethylated. Thus, the Oct-3/4 gene remains unmethylated at a time when the apoA1 gene undergoes de novo methylation. One possible mechanism to explain the ability of the Oct-3/4 gene to escape the first de novo methylation wave is the involvement of a cis-element that either actively demethylates the newly methylated Oct-3/4 or protects it from de novo methylation. At this stage of our research we cannot differentiate between these two alternatives, and for simplicity reasons this element will be designated a protection/demethylation or demodification element.
In the first series of experiments we wished to determine whether a long (1370 bp) fragment from the upstream regulatory element of the Oct-3/4 gene could bring about demethylation of an in vitro methylated substrate when integrated into the genome of P19 EC cells. This element contains the P, intervening, and PE sequences. We inserted this fragment into a vector (25) that was engineered to harbor a non-CpG island sequence as well as recognition sites for methylation-sensitive restriction endonucleases (designated pPEPwt, Figs. 1A and 2A). We generated stably transfected cell lines containing the above described in vitro methylated (by HpaII and HhaI methylases) construct and examined the methylation status of the insert as well as the vector sequences. To minimize the effect of particular integration sites and copy number, we analyzed more than 10 independent clones for each of the constructs tested and chose those with a similar copy number. The sites that were analyzed were the same HpaII and HhaI sites that were analyzed in the endogenous Oct-3/4 gene ( Fig. 1 ) and an extra HhaI site in the vector sequence ( Fig. 2A) . All sites analyzed were undermethylated (Fig. 2B, lanes 2 and 3) , indicating that this fragment harbors a demodification element that is able to demethylate sequences inside and outside the fragment. Next we analyzed the ability of the P alone, the proximal enhancer (PE) alone, and the P and PE elements without the intervening sequences to induce demethylation. It was clear that both the P and the intervening sequences are dispensable for the demethylation process (data not shown). In striking contrast, we found that the PE fragment (pPEwt) plays a key role in directing the demethylation reaction (Fig. 2B, compare  lanes 4 and 5) . This PE was previously found to be a critical element for P19 EC cell-specific expression and for RA-mediated down-regulation of the Oct-3/4 protein (1, 2).
We wished to determine whether the Oct-3/4 demodification element is specific for EC cells or alternatively functions in other cells as well. We transfected in vitro methylated pPEwt into L8 fibroblast cells and performed Southern blot analysis. This analysis showed that the integrated construct was resistant to HpaII and HhaI digestion and therefore maintained methylation at these sites (Fig. 2C, compare lane 1 to lanes 3  and 4) . Taken together, these experiments clearly indicate that the Oct-3/4 PE is required for directing demodification and for mediating demethylation of the Oct-3/4 gene in a cell-specific manner.
The 1A Site Is Crucial for the Demethylation Activity-This cell specificity encouraged us to delineate the demodification element responsible for Oct-3/4 demethylation in EC cells. It was shown previously (3, 5) that the PE contains two binding sites, 1A and 1B, which bind distinct factors in vitro, but only site 1A, which contains a conserved Sp1-like binding site, is occupied in vivo in undifferentiated ES and EC cells. To define whether the 1A and 1B sites are required for the demethylation process, the 1A site was mutated, and the 1B sequence was deleted in the context of both, the PE only (designated pPE1A*1B*), and the PE together with the P (designated pPEP1A*1B*). The pPEP1A*1B* was generated in order to analyze the ability of the mutated PE to induce demethylation not only upon vector sequences, which can be analyzed using pPE1A*1B*, but also upon HpaII and HhaI sites located in the Oct-3/4 P region. As can clearly be seen in Fig. 3A , mutating the 1A site and deleting the 1B site abolished almost completely bryos, 6.5, 8.5, and 14.5 dpc embryos, and P19 EC cells, and tail. DNA was digested with PvuII in the presence or absence of the indicated enzymes (Hp, HpaII; Hh, HhaI). Oligonucleotide primers flanking HpaII sites 1-4 (rows 1-4, respectively) and HhaI site (row Hh) of the Oct-3/4 upstream regulatory element were used for PCR amplification. As a control each DNA was amplified with primers 5SGL-2 and J1110 which amplify the J gene that do not encompass either HpaII or HhaI sites. PCR products were electrophoresed on 1-3% agarose gels, stained with ethidium bromide, and photographed. C, PCR analysis of the apoAI gene. Genomic DNA was isolated from blastocysts and epiblast of 6.25 dpc embryos. Oligonucleotide primers flanking HpaII and HhaI sites of the apoAI gene were used for PCR amplification. Each sample was amplified with control primers (described in B), and products were analyzed on agarose gels. D, the methylation level of HpaII sites 1-4 and the HhaI (Hh) site throughout embryogenesis and in the adult mice were quantified by PhosphorImager after subtracting the lane background signal and graphed. Percent methylation for each site, y axis, and embryonic stage (dpc), tail and kidney DNA, x axis, are shown. Genomic DNA was isolated from blastocysts, epiblasts of 6.25 dpc em-the ability of the PE to induce demodification of the vector and P sequences. These results strongly suggest that either 1A, 1B, or both sites play a critical role in the demethylation process and are most likely responsible for its cell type and developmental stage specificity.
To assess the roles of these two individual motifs in the process of demethylation, we designed two additional mutants that contained either mutation in the 1A sequence (designated pPE1A*) or a deletion of the 1B (designated pPE1B*). These mutations were only subcloned in the context of the PE because our previous results showed that all the HpaII and HhaI sites present in the pPEPwt construct were similarly modified, suggesting that the demodification element works in a regional manner. In vitro methylated pPE1A* and pPE1B* DNA were stably transfected into P19 cells, and DNA from more than 20 independent transfected clones were analyzed. This analysis revealed that deletion of the 1B sequence (leaving the 1A site intact) did not alter the ability of the demethylation element to demodify the Oct-3/4 HpaII site 1, and reduced its ability to demethylate the HhaI site located in the vector backbone (Fig.  3B, lanes 4 -6) . Strikingly, mutations in the 1A site were sufficient to abolish almost completely the ability of the Oct-3/4 PE element to induce demodification (Fig. 3B, lanes 1-3) . These data strongly suggest that the 1A site is a crucial part of the Oct-3/4 demodification element. Furthermore, it is clear that the 1B site is not sufficient to bring about demethylation. Taken together, the above results define a 270-bp segment (that does not contain the 1B site) from the Oct-3/4 PE as an embryonal specific demethylation element.
Because we have shown that demethylation of the Oct-3/4 gene is mostly guided by the 1A site, we attempted to find whether the above described mutations in this site result in loss of the PE binding activity. We carried out EMSAs using P19 cell extracts. Binding of this extract to the labeled 1Awt 32-bp (harboring the protected 1Awt region (3, 5)) probe generated three specific complexes (Fig. 4, A-C, lane 1) as follows: two prominent complexes, numbers 1 and 3 (the ratio between these two complexes changes in different experiments), and one faint complex (number 2). All three complexes were specifically competed by a 50-fold molar excess of a cold 1Awt oligonucleotide (Fig. 4A, lane 2, and B, lane 4) but not by an unrelated oligonucleotide (Fig. 4A, lane 3) . To test whether the Sp1 transcription factor binds the PE1A GC-rich Sp1-like binding site located at the PE1A, we performed a supershift experiment with antibodies directed against Sp1, and we found that indeed these antibodies supershifted a major part of complex 1 and not the other complexes (Fig. 4A, lane 5) . These results indicate that one of the proteins in complex 1 is the Sp1 transcription factor.
To determine whether the mutations in the PE1A, which abolished the demethylation activity, also abolish protein binding to the 1A sequence, we conducted EMSA with the 1Awt as the labeled probe, and we compared the ability of cold 1Awt and mut1A (that harbors the same mutations as in pPE1A*) oligonucleotides to compete for specific complex formation. All three complexes were almost completely inhibited by a 20-fold molar excess of the cold 1Awt oligonucleotide (Fig. 4B, lane 3) . In contrast, oligonucleotide mut1A did not compete at all (lanes  7-10) . Moreover, binding of P19 extracts to the labeled mut1A oligonucleotide resulted in either faint or nonspecific complexes (Fig. 4C, lanes 2 and 3) . Furthermore, mutations in PE1A completely abolished Sp1 binding to the DNA as seen by the inability of antibodies directed against Sp1 to supershift the complex (Fig. 4C, lane 3) .
The PE Fragment Protects Itself from de Novo Methylation in Vivo-On the basis of our above described data showing that the Oct-3/4 gene is unmethylated at 6.25 dpc embryo, and identifying the Oct-3/4 PE as an embryonal-specific demethylation element, we generated transgenic mice in order to test whether the PE element is also a major determinant in protecting the Oct-3/4 gene from de novo methylation in vivo. To this end, we generated two kinds of transgenic embryos. One contains the wt PE element and the other harbors the mutated PE1A*1B*, which is mutated in the 1A site and deleted at the 1B site. Epiblast cells were isolated from six embryos of 6.25 dpc (31) , and the methylation status of HpaII site 1, located inside the PE, was determined by methylation-dependent PCR analysis that was repeated 3 times. In agreement with the EC transfection experiments (Fig. 3) , the wt PE element stays unmethylated (Fig. 5 ), indicating that it is able to protect itself from de novo methylation occurring in these cells at this time in development. Interestingly, the mutated PE element underwent substantial de novo methylation in the 13 analyzed 6.25 FIG. 3 . The 1A site in the PE is crucial for its demethylation activity. A and B, P19 EC cells were transfected with the following methylated plasmids separately: pPE1A*1B* and pPEP1A*1B* (A), pPE1A* and pPE1B* (B), as emphasized by the diagram. DNA was digested with DraI in the presence or absence of the indicated enzymes (Hp, HpaII; Hh, HhaI), electrophoresed on a 1% agarose gel, blotted, and probed with the 826-bp DraI fragment. The faint bands observed are either from a cross-reaction with endogenous sequences (A, lanes 1-4) , or due to less than 10% demethylation (A, lanes 2, 3, 5, and 6 ). dpc embryos, indicating that an intact element is required to prevent local de novo methylation in vivo. Thus, the same mutations, located in the Sp1-like binding site, that destroy the PE demethylation and binding activities in EC cells also eliminate the ability of this sequence to protect itself from de novo methylation in the post-implantation embryo.
Oct-3/4 Methylation and Transcription-The Oct-3/4 gene undergoes de novo methylation both during embryogenesis (described above) and also in EC cells as a consequence of RA treatment (22) . To find out if methylation plays a significant role in the regulation of Oct-3/4 gene expression, two kinds of experiments were performed. The pOct-luc plasmid described previously (26) , containing the Oct-3/4 P region from position Ϫ413 (XbaI site) to ϩ48 (BanI), upstream from the luciferase reporter gene, as well as the newly generated pOctPE-luc harboring the P and the PE elements (Fig. 6A) were methylated in vitro, using either HpaII or HhaI methylases. Subsequently, the unmethylated and methylated plasmids were introduced transiently into P19 cells, and the luciferase activity was determined. Both plasmids behaved similarly to each other. As shown previously (8, 26, 30) , the unmethylated plasmids drive efficient transcription when transiently transfected into P19 cells. Transfectants containing the HhaI-methylated plasmids show a slightly reduced level of luciferase activity. Interestingly, HpaII methylation of the Oct-3/4 regulatory elements (either of the P alone or the P together with the PE) reduced luciferase activity to about 30%, relative to the activity of the unmethylated constructs (Fig.  6B ). These results demonstrate that the transcriptional activity 1-10) . Binding reactions were performed in the absence of competitors (comp.) (lanes 1 and 6) or in the presence of 5-100-fold molar excess of unlabeled 1Awt (lanes 2-5) and mut1A (lanes 7-10) oligonucleotides. C, the 32 P-labeled 1Awt (lane 1) and mut1A (lanes 2 and 3) oligonucleotides were incubated with WCE prepared from P19 EC cells. Binding reactions were performed in the absence of antibodies (lanes 1 and 2) , or in the presence of 1 g of anti-Sp1 antibody (lane 3).
of the Oct-3/4 upstream region is down-regulated by DNA methylation under transient transfection conditions.
These results prompted us to consider whether the same may be true for basal transcription associated with the Oct-3/4 locus in vivo. In order to test this possibility, we took advantage of a p53 Ϫ/Ϫ /Dnmt Ϫ/Ϫ (Dnmt; DNA methyltransferase) fibroblast cell line developed in Dr. Howard Cedar's laboratory. The p53 Ϫ/Ϫ knock out allows the propagation of a Dnmt Ϫ/Ϫ cells for a longer time (32) . Unlike wild type (wt) or p53 Ϫ/Ϫ fibroblasts, almost all of the CpG residues in these cells are unmethylated (data not shown). As shown in Fig. 6C , Oct-3/4 RNA synthesis was readily detected in p53 Ϫ/Ϫ /Dnmt Ϫ/Ϫ fibroblasts, whereas no Oct-3/4 could be detected in p53
Ϫ/Ϫ cells, using sensitive RT-PCR analysis. These data suggest that DNA methylation inhibits transcription of the endogenous Oct-3/4 gene as well.
It was shown previously that treatment of cells with the histone deacetylase inhibitor trichostatin A (TSA) (33, 34) partially overcomes the effects of DNA methylation on gene expression (35, 36) . In order to find whether this is also the case for the Oct-3/4 locus, we treated the cells with TSA and examined Oct-3/4 basal transcription. Treatment of p53 Ϫ/Ϫ /Dnmt Ϫ/Ϫ cells resulted in no induction of the Oct-3/4 transcript level, probably due to the already acetylated nature of the Oct-3/4 chromatin surrounding the unmethylated substrate (Fig. 6C) . Interestingly, TSA treatment of p53 Ϫ/Ϫ cells also did not help to induce any detectable level of Oct-3/4 transcription, most probably due to the ability of DNA methylation to inhibit basal transcription that cannot be overcome by a change in the acetylation status of the chromatin.
DISCUSSION
The Oct-3/4 gene provides a unique model system to study the molecular parameters that underlie the generation of the methylation status of genes that are expressed during early embryogenesis and are repressed following implantation around gastrulation. By analyzing the Oct-3/4 methylation status during embryogenesis, we have shown that the Oct-3/4 upstream regulatory region is unmethylated in blastocysts and in 6.25 dpc epiblast cells and becomes methylated in 6.5 dpc embryos almost to the full extent, similar to adult tissues (Fig.  1, B and D) . Interestingly, it seems that there is a core methylation center in the PE, encompassing HhaI and HpaII site 3, which is almost fully modified, whereas sequences that flank this center are gradually less methylated as a function of their distance from the center (Fig. 1E) .
DNA methylation is known to have profound effects on both chromatin structure and gene expression (37-39). Our current and previously published data (22) indicate that Oct-3/4 methylation status is highly compatible with Oct-3/4 expression.
Our experiments clearly demonstrate that methylation inhibits transcription of transfected genes regulated by the Oct-3/4 upstream region (Fig. 6B) . Furthermore, methylation inhibits FIG. 5 . PCR analysis of the Oct-3/4 PE in transgenic mice. Six PEwt and 13 double-mutated PE1A*1B* 6.25 dpc transgenic embryos were collected. Epiblast cells were isolated, and DNA was extracted and subjected to digestion with PvuII in the presence (ϩ) or absence (Ϫ) of HpaII (Hp). Oligonucleotide primers flanking HpaII site 1 were used for PCR amplification. As a control, each DNA was amplified with primers 5SGL-2 and J1110 which amplify the J gene that does not encompass HpaII sites. PCR products were electrophoresed on 2% agarose gels, stained with ethidium bromide, and photographed. This analysis was repeated 3 times, and a representative experiment is shown.
FIG. 6. Methylation represses
Oct-3/4 upstream regulatory elements activity. A, maps of the pOct-luc and pOctPE-luc reporter plasmids. The XbaI/BanI fragment, spanning positions Ϫ413 to ϩ48 of the Oct-3/4 P region, was inserted upstream to the luciferase reporter gene in pBluescript II KS to generate pOct-luc (26) . The BamHI/BamHI fragment, spanning positions Ϫ1215 to ϩ155 of the Oct-3/4 region containing the P and PE elements, was inserted upstream to the luciferase reporter gene in pBluescript II KS to generate pOctPE-luc. B, the pOct-luc or the pOctPE-luc constructs were transiently cotransfected into P19 EC cells either un-methylated or methylated with the indicated enzymes (Hp, HpaII methylase; Hh, HhaI methylase) together with the pCMV-Renilla luciferase construct. Luciferase and Renilla luciferase activities were determined 48 h post-transfection, and each separate transfection was normalized to the Renilla luciferase activity. Percent luciferase activity values are relative to the un-methylated respective construct that was set at transcription of the endogenous Oct-3/4 gene, because in cells in which most of the CpG residues are unmethylated Oct-3/4 transcripts are readily detected. TSA treatment that modifies the chromatin structure did not induce Oct-3/4 transcription from a methylated substrate, indicating that in these cells histone acetylation cannot override inhibition by DNA methylation (Fig. 6C) .
Recently, it was shown that relative minor changes in Oct-3/4 protein expression exert a dramatic effect. For instance a 50% decrease in the Oct-3/4 protein levels causes the cell to differentiate into trophectodermal cells (14) . A consequence of this finding is the necessity for fine-tuning of Oct-3/4 gene regulation. Indeed, a number of studies (26, 40 -42) have shown that several orphan members of the nuclear receptor gene superfamily are involved in repression of Oct-3/4 expression. Our study indicates that repression of Oct-3/4 expression is brought about not only by trans-acting transcriptional repressors but also by epigenetic mechanisms, such as DNA methylation. It is possible that silencing of Oct-3/4 by methylation is a secondary event to another epigenetic mechanism such as chromatin modifications. This in fact could explain our findings that in blastocysts no methylation is observed (Fig. 1B) , although the gene is repressed in trophoblasts at this stage.
Oct-3/4 Demodification Element and Embryogenesis-Oct-3/4 expression is dependent on at least three upstream cisregulatory regions: the P, the PE, and a distal enhancer (3, 5, 8, 12, 41, 43) . Our results clearly show that the PE element is not only a transcriptional enhancer but it is also a cis-demodification element that demethylates/protects the DNA in a cell-and stage-specific manner. The observation that enhancer sequences are part of several identified demodification elements (20, 27, 44 -46) and the fact that demethylation does not seem to occur as a consequence of transcriptional activation (47) (48) (49) strongly suggest that enhancers may have two separate and independent functions, first to target genes for epigenetic modification and second to stimulate RNA synthesis.
The PE sequence in the Oct-3/4 gene harbors two sites, 1A and 1B, that in vitro bind distinct and currently unidentified factors. The 1A site, located between conserved regions of homology 2 and 3 (50) , contains the sequence GGGAGGG that is conserved among mouse, human, and bovine Oct-3/4 upstream region. This site is occupied in vivo in undifferentiated EC and ES cells (3, 5) . Repression of Oct-3/4 transcription through the PE by RA treatment is coupled with the displacement of factors from site 1A, indicating that in cells expressing the Oct-3/4 gene, transcriptional activators bind this site. Interestingly, our data show that site 1A, and not 1B, plays a critical role in the demethylation reaction (Fig. 3B) . Thus, our results correlate well with the previously published data showing that site 1A is the crucial site for transcriptional activation in vivo.
A number of previously published studies (16, 17) indicate that most of the CpG sites in the genome, located in expressed and non-expressed sequences, are unmethylated in the blastula. Between implantation and gastrulation a wave of de novo methylation re-establishes the overall methylation pattern, which is then maintained throughout life in the somatic cells of the animal, except for the demethylation of some tissue-specific genes during differentiation (51) . Our data indicate that during embryogenesis Oct-3/4 remains unmethylated, whereas other genes undergo de novo methylation (similarly to genes on the inactive X chromosome (52)). Theoretically, it is possible that the overall wave of de novo methylation does modify the Oct-3/4 gene along with other sequences, but it continuously undergoes demethylation due to the presence of an active demodification element. The other possibility is that Oct-3/4 harbors a ciselement that is bound by proteins that protect the gene from the methyltransferases that operate at this time of embryogenesis. Our studies do not differentiate between the two possibilities; however, because the DNA is initially unmethylated, we postulate that in vivo the Oct-3/4 PE element protects the DNA from de novo methylation in 6.25 dpc post-implantation embryos (Fig. 5) . Because the tissue composition of the 6.5 dpc embryo is different from the composition of the 6.25 dpc embryo, it is possible that in a small number of cells that do express the Oct-3/4 protein in the 6.5 embryo the PE element still protects the gene from de novo methylation. It is highly likely that this element is bound by trans-acting factors that prevent access to the DNA from the methylation machinery. It was shown previously that DNA-binding proteins are able to protect sites from de novo methylation as well as specify sites for demethylation (49, 53) . These factors may recruit additional cell-specific proteins (with histone modification capabilities (54) ) to the region, thereby protecting the local region from de novo methylation under circumstances where the sequence is initially unmethylated or demethylating the region when the sequence is first methylated.
Once we have identified the PE as a demethylation/protection element in the Oct-3/4 gene, it is pertinent to ask where else (besides in epiblast cells) this element is active in vivo. There are two obvious cell types where it may play a role. The first candidates are cells in the post-implantation embryo. Because Oct-3/4 expression persists through 7.5 dpc embryo in the unsegmented presomitic mesoderm, decreasing anteriorly to posteriorly as the somites form until 8.5 dpc (1, 7, 9) , it is logical to suggest that the Oct-3/4 demethylation/protection element protects the gene from becoming modified in these subpopulations of cells as well.
Additionally, the PE demethylation element could play a role during differentiation and maturation of gametes of both sexes. Throughout spermatogenesis de novo methylation is very well orchestrated, occurring later than global methylation in somatic cells and at least in three waves as follows: the first at 15.5-17.5 dpc, the second in the vas deferens, and the third that methylates imprinted genes only (55, 56) . The Oct-3/4 gene stays unmethylated almost to the last developmental stage of spermatogenesis, in the face of the global de novo methylation wave that occurs in pro-spermatogonia (56) . It is reasonable to suggest that the novel Oct-3/4 demodification element protects the Oct-3/4 gene from the first but not from the second or third waves of de novo methylation.
In the female gonads, Oct-3/4 is expressed until 15.5 dpc (when de novo methylation occurs) and is down-regulated as the oocyte enters prophase I (at 16.5 dpc) to be again expressed FIG. 7 . A model for generation of Oct-3/4 methylation pattern. During the early stages of embryogenesis (up to 8.0 dpc) and most probably during spermatogenesis and oogenesis, specific trans-acting factors (red) bind the 1A site in the PE element and protect the surrounding sequences from global de novo methylation which leads in turn to Oct-3/4 undermethylation and expression. At later stages of embryogenesis (post-8.5 dpc) and in the adult, these factors are either absent (left part of Fig. 7) or different trans-acting factors (purple hexamer) bind (right part of the figure), and the Oct-3/4 undergoes methylation de novo and silencing.
in oocytes within primary follicles and at the onset of oocyte growth and folliculogenesis (1-2 dpc) (9, 10). The methylation pattern of the Oct-3/4 gene during oogenesis has not been studied. However, there is a striking correlation between the global de novo methylation timing and Oct-3/4 down-regulation. Thus, because in oocytes Oct-3/4 is re-expressed after birth, it is logical to suggest that the PE demethylation element may also play a role in protecting the Oct-3/4 gene from undergoing de novo methylation at 15.5 dpc and therefore allowing for its later re-expression during oogenesis. Thus, the PE element protects the gene during early development and is a very good candidate for a germ cellspecific demethylating element.
It was shown previously (18, 19) that the mouse has a preprogrammed mechanism to ensure that CpG islands at the 5Ј end of all housekeeping genes remain unmethylated to allow expression. Sp1-like binding sites are frequently associated with CpG islands, where they protect the islands from undergoing de novo methylation (18, 19) . We propose that the mouse has also a similar mechanism to ensure undermethylation and expression of genes that are specifically expressed through a particular window of time during embryogenesis, when de novo methylation occurs. A representative of this group of genes is Oct-3/4. Indeed, our data clearly show that the Oct-3/4 PE1A site that is GC-rich and is related to the consensus Sp1-binding site binds several proteins. We have shown that in an in vitro assay the Sp1 transcription factor is one of them. Most interestingly, the 1A site protects the DNA from de novo methylation in vivo (Fig. 5) . This is not to say that every Sp1-binding site harbors the ability to protect the surrounding sequence from de novo methylation. In fact, it was shown previously (25) that an Sp1-binding site on its own is not sufficient for demethylation in vivo. However, it is logical to suggest that during early stages of development specific Sp1-like binding sites together with as yet unidentified cis sequences not only protect/ demethylate CpG islands in housekeeping genes but also modify sequences located in cell-specific genes, which do not contain CpG islands but contain other permissive sequences, such as the Oct-3/4 PE element.
Methylation of the Oct-3/4 gene is most likely a part of a regulatory process that takes place independently of the major wave of de novo methylation. In the Oct-3/4 gene case the methyl moieties are actually added to the DNA later than in genes that are not expressed at this particular time in development. This process may resemble the late addition of methyl groups to CpG islands on the inactive X chromosome (57) . On the basis of our above described data, we propose the following model for the generation of Oct-3/4 methylation pattern. During the post-implantation period and most probably during germ cell formation, specific trans-acting factors bind to the PE element and protect the surrounding sequences from the global de novo methylation which lead in turn to expression of the gene. During later stages of embryogenesis, these factors are probably absent, and the Oct-3/4 gene undergoes de novo methylation and silencing. This could happen by a default mechanism due to the lack of proteins that bind to the PE sequences or through binding of different kinds of transcription factors (Fig. 7) .
